DOL Compliance Tools & PBM Regulation, NLRB Intake Updates - #WorkforceWednesday® - Employment Law This Week®
Health-e Law Podcast, Episode 20 | J.P. Morgan Healthcare 2026 and Beyond: How Digital Innovation Shapes Healthcare M&A
Podcast - Minority Deals in Healthcare Private Equity: An Evolving Opportunity for GPs and Founders Counsel That Cares Podcast Series
Pay Transparency + the Power of Preventive Strategies: Episode 3 — Pivoting Toward Preparation in the Life Sciences
Pay Transparency + the Power of Preventive Strategies: Episode 2 — Healthcare Compliance Crossroads
Hospice Insights Podcast - Reimagining How We Navigate Change and Loss: A Conversation with Sonya Dolan and Bridget Sumser of Mettle Health
Podcast - The Fast-Growing Wound Care Industry
Concierge Practices: Getting Started and Staying Compliant
Podcast - J.P. Morgan Healthcare Conference Recap: What Dealmakers Expect in 2026
Illinois Supreme Court Tightens Standing for No-Injury Consumer Claims — The Consumer Finance Podcast
Work This Way: A Labor & Employment Law Podcast | Service Animals, the ADA, and Workplace Rights
Episode 265: Redesigning Clinical Trials Through Technology with Patrick McCarthy of Validcare
From Diligence to Post-Closing: What’s Shifting in 2026 Health Care Transactions
Private Equity Investment in Health Care
Healthcare Trend Report: A Review of the Pharmacy and Drug Supply Chain Sectors
Point-of-Sale Finance Series: Health Care Financing Compliance, Regulatory, and Privacy Pitfalls — Payments Pros – The Payments Law Podcast
Point-of-Sale Finance Series: Health Care Financing Compliance, Regulatory, and Privacy Pitfalls — The Consumer Finance Podcast
AGG Talks: Government Insight for Life Sciences Leaders | Patient Assistance Programs and the False Claims Act: Enforcement Trends and Compliance Risks for Life Sciences Companies
Health-e Law Episode 19: From AI to OBBBA: Healthcare Law Insights from the 2025 WHLC Leadership Summit with Amy Dilcher and Chi Huynh, WHLC Co-Chairs
Video Overview: Healthcare Trend Report - A Review of the Pharmacy and Drug Supply Chain Sectors
U.S. Congress will largely return to normal operations this week, following passage of an appropriations package on February 3, 2026, that will fund the vast majority of federal agency operations through the end of 2026. ...more
The life sciences investment climate is looking up, as industry adapts to challenging supply-side forces and AI makes inroads in healthcare....more
Our most recent installment of Kelley Drye’s State Attorney General Webinar Series featured a conversation with representatives of the West Virginia Attorney General’s Office, including Chief Deputy Jace Goins, Consumer...more
North Carolina state government leaders this year are likely to consider important issues including a state budget bill, funding for education and health care (including Medicaid), and various policy issues....more
The Q1 and Q3 Life Science and Health Care Law Update covers key trends in the EU only while the other reports (on Q2 and Q4) cover key trends in the EU as well as in the Big Five (France, Germany, Italy, Spain, UK) in life...more
Unless your medical practice “creates or maintains” substance use disorder (SUD) records covered by federal law (42 CFR Part 2), you can ignore the barrage of panic-inducing emails you have been receiving informing you that...more
Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary...more
Across late December 2025 and early January 2026, multiple developments point to a broad tightening of standards and oversight that directly affects DSOs as they scale. At the industry level, the ADA’s decision to launch a...more
Many Title IX coordinators, directors of disability services, and conduct officers serve on Behavioral Intervention Teams (BITs) or Threat Assessment Teams (TATs), and their roles bring valuable perspectives. Sometimes, their...more
On Feb. 3, 2026, President Donald Trump signed into law the FY 2026 appropriations bill, the Consolidated Appropriations Act of 2026, which extends pandemic-era Medicare telehealth flexibilities through Dec. 31, 2027....more
Cybersecurity is no longer just an IT or privacy issue. For FDA regulated companies, it’s a patient safety issue, a product quality issue, and increasingly a regulatory enforcement issue. FDA has made it clear that...more
On Feb. 3, 2026, President Donald Trump signed into law the Consolidated Appropriations Act, 2026 (CAA 2026), a sweeping piece of legislation including provisions that will substantially impact employer-sponsored health...more
Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide injections and pills infringe on its patent covering the active pharmaceutical...more
On January 22, 2026, the Fraud Section of the U.S. Department of Justice’s (DOJ) Criminal Division published its Year in Review for 2025. The report summarizes activity across the Fraud Section’s Health Care Fraud (HCF),...more
This regular publication by DLA Piper lawyers focuses on helping clients navigate the ever-changing business, legal, and regulatory landscape. FDA releases 2026 deliverables for Human Foods Program. On January 23, the Food...more
On Feb. 1, 2026, the FDA officially launched its Manufacturing PreCheck Pilot Program, which is intended to de-risk and accelerate the establishment of U.S. pharmaceutical manufacturing facilities by increasing regulatory...more
Reproductive health privacy rule vacated. On June 18, 2025, the U.S. District Court for the Northern District of Texas vacated the HIPAA Privacy Rule to Support Reproductive Health Care Privacy Final Rule (Privacy Rule)....more
During a recent industry webinar, Cara Welch, Ph.D., Director of the Office of Dietary Supplement Programs (“ODSP”) within the U.S. Food and Drug Administration (“FDA”), outlined the agency’s 2026 priorities for the dietary...more
The U.S. Food and Drug Administration ("FDA") released a draft guidance document in January 2026 titled "FDA Records Access Authority for Cosmetic Products: Guidance for Industry" (the “Draft Guidance”). The Draft Guidance...more
On February 3, 2026, the President signed the Consolidated Appropriations Act of 2026 (the CAA) into law and ended a partial government shutdown. The Act included two changes that directly affect pharmaceutical development:...more
The federal government recently delivered back-to-back measures forcing pharmacy benefit managers (PBMs) to be more transparent about their business models. However, with this heightened transparency comes a host of new...more
Fiscal year (FY) 2025 was a groundbreaking year for the False Claims Act (FCA) in several respects. Recoveries under the statute reached an all-time high of nearly $7 billion, more than double those in each of the prior...more
On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively. ...more
OCR is increasing enforcement around parental access to minors’ health information, emphasizing that parents are generally entitled to access their child’s PHI under HIPAA....more
This week, we discuss the Department of Labor’s (DOL’s) new compliance tools, its proposed pharmacy benefits manager (PBM) transparency regulation, and updated enforcement priorities from the DOL’s Employee Benefits Security...more
